Undisclosed SIRPα-PD-L1 bispecific antibody
/ Sairopa
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
A novel SIRPαxPD-L1 bispecific antibody remodels the innate and adaptive tumor microenvironment, and enhances tumor control
(AACR 2025)
- "Remarkably, SIRPαxPDL1 synergized with a tumour-targeting antibody, further augmenting tumor control and survival. These findings highlight, for the first time, the potential of SIRPαxPDL1 to remodel the myeloid compartment and activate antitumor immunity, offering a promising novel avenue in cancer immunotherapy and combination approaches."
Biomarker • Tumor microenvironment • Oncology • CD8 • SIRPA
1 to 1
Of
1
Go to page
1